AI assistant
Phathom Pharmaceuticals, Inc. — Director's Dealing 2022
Apr 7, 2022
32407_dirs_2022-04-06_c4607a08-0567-4485-b360-0e091edc2c7a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2022-04-05
Reporting Person: Henderson Molly (CFO and CBO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-04-05 | Common Stock | A | 20000 | $0.00 | Acquired | 20000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-04-05 | Stock Option (Right to Buy) | $15.08 | A | 100000 | Acquired | 2032-04-04 | Common Stock (100000) | Direct |
Footnotes
F1: Represents restricted stock units ("RSUs") granted on April 5, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of April 5, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2: The stock option will vest with respect to 25% of the shares of common stock on April 5, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.